Incremental Treatment Costs in National Cancer Institute-Sponsored Clinical Trials

JAMA

Volumn 289, Issue 22, 2003, Pages 2970-2977

  Goldman, Dana P ^a,f   Berry, Sandra H ^a   McCabe, Mary S ^b   Kilgore, Meredith L ^c   Potosky, Arnold L ^b   Schoenbaum, Michael L ^a   Schonlau, Matthias ^a   Weeks, Jane C ^d   Kaplan, Richard ^b   Escarce, José J ^a,e  

^a RAND CORPORATION   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER CENTER; CANCER MORTALITY; CANCER PATIENT; CANCER RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; GOVERNMENT; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; MEDICARE; PATIENT CARE; PRIORITY JOURNAL; REIMBURSEMENT; UNITED STATES; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH CARE ORGANIZATION; NEOPLASM; RETROSPECTIVE STUDY;

ADULT; CLINICAL TRIALS; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; RESEARCH SUPPORT; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 0037805274     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.22.2970     Document Type: Article

References (35)

1. Fleming ID. Barriers to clinical trials, I: reimbursement problems. Cancer. 1994;74(suppl 9):2662-2665.
2. Schain WS. Barriers to clinical trials, II: knowledge and attitudes of potential participants. Cancer. 1994;74(suppl 9):2666-2671.
3. Mansour EG. Barriers to clinical trials, III: knowledge and attitudes of health care providers. Cancer 1994;74(suppl 9):2672-2675.
4. NIH clinical trials. Various Factors Affect Patient Participation. Washington, DC: US General Accounting Office; September 1999. Publication No. GAO/HEHS-99-1821.
5. National Institutes of Health Consensus Conference. Treatment of early-stage breast cancer. JAMA. 1991;265:391-395.
6. National Institutes of Health Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444-1450.
7. Fisher B, Redmond C, Poisson R, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1989;320:822-828.
8. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483-2493.
9. Perez EA, Hesketh P, Sandbach J, et al. Comparison of single-dose oral granisetron vs intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol. 1998;16:754-760.
10. Aaron HJ, Gelband H, eds. Extending Medicare Reimbursement in Clinical Trials. Washington, DC: Institute of Medicine, National Academy Press; 2000.
11. Wagner JL, Alberts SR, Sloan JA, et al. Incremental costs of enrolling cancer patients in clinical trials: a population-based study [published correction appears in J Natl Cancer Inst. 2000;92:164-165]. J Natl Cancer Inst. 1999;91:847-853.
12. Wagner JL, Alberts SR, Sloan JA, et al. Incremental costs of enrolling cancer patients in clinical trials: a population-based study [published correction appears in J Natl Cancer Inst. 2000;92:164-165]. J Natl Cancer Inst. 1999;91:847-853.
13. Fireman B, Fehrenbacher L, Gruskin EP, et al. Cost of care for patients in cancer trials. J Natl Cancer Inst. 2000;92:136-142.
14. Quirk J, Schrag D, Radzyner M, et al. Clinical trial costs are similar to and may be less than standard care, and inpatient charges at an academic medical center are similar to major, minor, and nonteaching hospitals. In: Program and abstracts of annual meeting of the American Society of Clinical Oncology; May 2000; New Orleans, La.
15. Stinson TJ, Bennett CL, Vogel V, et al. A multicenter study of the costs of enrolling cancer patients in phase II clinical trials. In: program and abstracts of the annual meeting of the American Society of Clinical Oncology; May 2000; New Orleans, La.
16. Chirikos TN, Ruckdeschel JC, Krischer JP. Impact of dinical trials on the cost of cancer care. Med Care. 2001;39:373-383.
17. Brown ML. Cancer patient care in clinical trials sponsored by the National Cancer Institute: what does it cost? J Natl Cancer Inst. 1999;91:818-819.
18. Goldman DP, Schoenbaum ML, Potosky AL et al. Measuring the incremental cost of clinical cancer research. J Clin Oncol. 2001;19:105-110.
19. Goldman DP, Adams JL, Berry SH, et al. The Cost of Cancer Treatment Study's Design and Methods. Santa Monica, Calif: RAND; 2000. Publication No. MR-1169-NCI/NIH/OSTP.
20. Schoenbaum M, Kilgore ML, Weidmer BA, Berry SH, Escarce JJ, Goldman DP. Using Hospital Tumor Registries to Identify Research Subjects. Health Serv Outcomes Res Methodol. 2001;2:67-76.
21. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31:732-748.
22. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40(8 suppl):IV-104-117.
23. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998;17:283-295.
24. Cochran WG. Sampling Techniques. 3rd ed. New York, NY: John Wiley & Sons; 1977.
25. Roche K, Paul N, Smuck B, et al. Factors affecting workload of cancer clinical trials: results of a multicenter study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2002;20:545-556.
26. Glicksman AS. Strategies For Evaluating New Therapeutic Options Under Managed Care. Washingtion, DC: National Cancer Institute, President's Cancer Panel; 1996. Available at: http://deainfo.nci.nih .gov/ADVISORY/pcp/archive/pcp1096/glicksma .htm. Accessed April 16, 2003.
27. Martin JB. Academic-industrial collaboration: the good, the bad, and the ugly. TRANS Am Clin Climatol Assoc. 2002;113:227-239.
28. Paller MS, Hostetler L, Dykjuis DA. Clinical trials at AHCs: the perspective of an academic clinical trials office. Acad Med. 2002;77:1201-1206.
29. Simon MS, Brown DR, Du W, LoRusso P, Kellogg CM. Accrual to breast cancer clinical trials at a university-affiliated hospital in metropolitan Detroit. Arn J Clin Oncol. 1999;22:42-46.
30. Lara PN Jr, Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001;19:1728-1733.
31. Siminoff LA, Zhang A, Saunders Sturm CM, Colabianchi N. Referral of breast cancer patients to medical oncologists after initial surgical management. Med Care. 2000;38:696-704.
32. Siminoff LA, Zhang A, Colabianchi N, Sturm CM, Shen Q. Factors that predict the referral of breast cancer patients onto clinical trials by their surgeons and medical oncologists. J Clin Oncol. 2000;18:1203-1211.
33. Benson AB III, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J Clin Oncol. 1991;9:2067-2075.
34. Braunholtz DA, Edwards SJ, Lilford PJ. Are randomized clinical trials good for us (in the short term): evidence for a "trial effect." J Clin Epidemiol. 2001;54:217-224.
35. Solicitation of public comments on exception under section 1182A(a)(5) of the Social Security Act. 76 Federal Register 236 (2002 Dec).